Recent years have brought a rise in newly emergent viral infections, primarily in the form of previously known arthropod-transmitted viruses that have increased significantly in both incidence and geographical range. Of particular note are DENV, CHIKV, and ZIKV, which are transmitted mostly by Aedes species of mosquitoes that exhibit a wide and increasing global distribution. Being important pathogens for the general population, these viruses have the potential to be devastating in the international transplant community, with graft rejection and death as possible outcomes of infection. In this review, we discuss the current state of knowledge for these viruses as well as repercussions of infection in the solid organ and HSCT population, with a focus, when possible, on pediatric patients. 
| INTRODUC TI ON
Arboviruses, such as West Nile virus, have previously proven problematic in the transplant community, with donor-derived and mosquito-transmitted infections causing severe neuroinvasive disease, high morbidity, and mortality. [1] [2] [3] [4] [5] Although many arboviruses are reemerging, DENV, CHIKV, and ZIKV pose the highest new risk to transplant recipients as they have been recently associated with large epidemics of disease and are becoming endemic in a wider geographical range than ever before. Circulation of these viruses has expanded due to multiple factors, including population growth, travel, climate change, and insufficient vector control. [6] [7] [8] These viruses are unique among arboviruses in that they generate high titer viremia in humans sufficient to maintain a human-mosquito-human transmission cycle, which enables large urban outbreaks of infection. Even in endemic areas with broad preexisting immunity, low infection rates and the presence of animal reservoirs allow for continued transmission of these viruses. Individuals infected with any of these arboviruses can be asymptomatic or present with a typically mild and self-limited febrile illness accompanied by malaise, rash, and myalgia or arthralgia. As these viruses continue to cause largescale outbreaks and expand geographically, bringing awareness to the potential risks to immunocompromised transplant recipients is important for prevention, diagnosis, and treatment. In this review, we discuss the current state of knowledge for these viruses as well as repercussions of infection in the SOT and HSCT population, with a focus, when possible, on pediatric patients.
As with other pathogens, the transplant population is at increased risk of acquiring infection and experiencing severe disease caused by these arboviruses due to immunosuppression and, specifically, impaired T-cell function. 9 Although each virus discussed in this review elicits specific immune responses that do not fully 12 Oral ulcers (rare) 59 Retro-orbital pain (38%) 12 Conjunctivitis (77%) 12 Conjunctivitis (29%) 75 URI symptoms (14%) 75 Retro-orbital pain (48%) 12 Conjunctivitis (82%) 12 CV Hypotension (19%) 19 Vascular leak (26.5%) 107 Shock (infants) 108 Not reported
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| Clinical manifestations-adult
Up to 75% of DENV infections are asymptomatic in all age-groups, 17 but the symptomatic individual can present within a range of disease severity ( 
| Clinical manifestations-pediatric
The common pediatric manifestations of DENV include fever, irritability, and feeding refusal in infants (Table 1) . In older children, fever and vomiting are common, though arthralgia and myalgia are less common than in adults. Cough is prevalent in patients with pleural effusion or ARDS. Although rare in the pediatric population, bleeding of skin and mucosal surfaces is common in children with more severe disease. 19 Infants aged 4-9 months and children aged 5-7 years are at higher risk of severe disease, and as with adults, secondary DENV infection is a risk factor for severity. 20 Symptoms such as shock, plasma leakage, and marked thrombocytopenia are more severe and frequent in children than in adults. 21 
| Infections in transplant patients
Due to DENV global prevalence, more information on DENV in transplant patients is available than for CHIKV and ZIKV, with over 200 reported cases in transplant patients (HSCT, liver, and kidney), though mostly in adults [22] [23] [24] [25] [26] [27] (Tables 2 and 3) . DENV can present atypically in transplant patients, such as acute colitis 28 or encephalitis. 29 The presentation of DENV in renal transplant patients is less characterized by fever, myalgia, arthralgia, and headache, while pleural effusion and ascites were more often observed. 23 Severe DENV was significantly more common among transplant patients (16% vs 3.7%) and had a significantly higher mortality (8.9% vs 0.062%). 24 Age and immunosuppressive agents have not yet been reported to affect disease severity, mortality, or graft outcome. However, transplant patients can have prolonged viremia, up to 80 days in one report, as opposed to median of 5 days in immunocompetent patients. 22 Importantly, 25% of transplant patients with primary disease did not mount an IgG response after 15 weeks of illness, making this an unreliable diagnostic test for this population. Moreover, nearly 60%
had graft dysfunction during the illness. 23 Multiple severe and fatal cases of dengue have been reported in renal transplant patients, as well as a fatality in a liver recipient. 24, 30 In fatal cases, disease developed within the first month after transplant. Occurrence of DHF, especially in the early post-operative period, can be particularly dangerous, with two patients reported to have had thrombocytopenia, platelet dysfunction, and coagulopathy resulting in profuse bleeding around the renal graft and one case of graft loss. 31 DENV acquisition has been described both from mosquito exposure and via graft transmission for both HSCT 32, 33 and SOT. 26, 34, 35 Transfusion-related DENV transmission has also been reported. 36, 37 Due to the risk of disease severity, appropriate pre- the patient demonstrated hemodynamic instability that was not controlled with pressors or additional blood products, and the patient ultimately died of cardiac arrest. The second patient was 21 years old and also had an uneventful transplant. He was initially given antibiotics post-operatively because the donor was receiving antibiotics.
He developed fever, anuria, pain at the surgical site, and pancytopenia on POD 3. CT revealed fluid in the perirenal site, and he underwent three surgeries and several transfusions of blood products to achieve hemostasis. He was diagnosed with DENV on POD 6 via blood RT-PCR. He ultimately recovered and was discharged.
A 16-year-old kidney recipient in Thailand experienced a severe case of DENV. She developed ascites, bilateral pleural effusions, and thrombocytopenia without fever on day 13 after transplant. She also developed refractory pancytopenia and anemia resulting in hypovolemic shock and graft failure 28 days after transplant. She was found to have a large perirenal hematoma that required surgical evacuation, but gradually recovered and was discharged. 39 Another Thai 16-year-old patient received an allogeneic peripheral blood stem cell transplant for acute myeloid leukemia. She acquired DHF 5 months after transplant and made a full recovery after 14 days of hospitalization. 40 It is not known whether the patients in the first three of these case reports acquired DENV via the graft, but the timing of infection raises this concern. The HSCT patient likely was infected via the bite of an infected Aedes mosquito. 
| Screening and diagnosis

| Advances in prevention and treatment
There is a DENV vaccine, CYD-TDV, or Dengvaxia, which is licenced in 20 countries for individuals between 9 and 45 years of age. The risk of severe DENV after vaccination of seronegative patients has not been studied in the immunosuppressed population.
As for recent advances in DENV-targeted therapy, there has been some promise in mouse models using a combination of sunitinib, a VEGF receptor tyrosine kinase inhibitor, and TNF inhibitors for the reduction in vascular leak and protection from lethal disease. 46 TNF inhibition has also been useful in limiting DENV-induced encephalitis in mouse models. 47 IVIG has been successfully used to halt capillary leak and hemodynamic instability in a renal transplant patient. 27 Quinine sulfate inhibits in vitro replication of all four DENV serotypes. 48 Targeted monoclonal antibodies are also under investigation for the capacity to prevent or reduce infection or disease. 49 At the mosquito transmission level, Wolbachia (a bacteria that infects mosquitoes) is being developed to prevent DENV transmission and could prevent other mosquito-borne infections as well. 50 Unfortunately, drug trials with balapiravir, 51 chloroquine, 52 lovastatin, 53 and celgosivir 54 have not demonstrated these agents to be clinically effective against DENV.
| CHIKUNG UNYA VIRUS
| Virus and epidemiology
CHIKV is a positive-sense, single-stranded RNA virus from the 
| Clinical manifestations-adult
After the bite of an infected mosquito, viral replication in different cell types within the skin takes place, followed by the viremic phase, which disseminates virus into the bloodstream. Secondary sites of infections include muscles, joints, liver, spleen, and brain. A hallmark of CHIKV infection is chronic polyarthralgia, with joint pain lasting months to years after infection in a significant proportion (~43%) of infected individuals (Table 1) . 58 It is thought that chronic CHIKV disease is due to host immune responses, though persistent infection cannot yet be ruled out.
| Clinical manifestations-pediatric
Children infected with CHIKV are likely to present with fever and rash, with febrile seizures often described, but they less commonly exhibit arthralgia, myalgia, or headache 59 (Table 1 ). Children are also more likely to have bleeding symptoms, including purpura, ecchymosis, and severe bleeding from mucosal surfaces. Perinatal infection was first described in 2005 60 and approaches 50% when mothers are viremic in the week preceding delivery, likely due to exposure during or soon after delivery. Neonates present with fever, rash, and edema within the first week of life, and complications can be devastating, including intracerebral hemorrhage, status epilepticus, multiorgan failure, and death. Early clearance of CHIKV in pediatric cases is associated with a strong innate immune response. 
| Infections in transplant patients
Few cases of CHIKV have been reported among organ transplant recipients (Table 3 ). An adult liver recipient on azathioprine and prednisolone developed CHIKV disease 7 years post-transplant, complicated by encephalitis, though he had no joint symptoms and recovered completely. 61 A woman with HIV and kidney transplantation developed high fever, diarrhea, and nausea for 2 days, and persistent headache, fatigue, myalgia, and severe, bilateral, symmetrical arthralgia after CHIKV infection, with the development of persistent arthralgia in follow-up. 62 A study of 13 SOT recipients (nine kidney, four liver) infected with CHIKV exhibited a similar clinical presentation to immunocompetent hosts, including chronic joint symptoms in 46% of patients 3 months after infection. 63 However, there were no incidents of complications or death and these transplant patients 
| Screening and diagnosis
Laboratory confirmation of CHIKV requires virological or serological tests. RT-PCR can detect virus in the blood during the first 5 days of infection. After that, anti-CHIKV IgM and IgG antibodies may be present. IgM antibodies peak at 3-5 weeks and decline at 2 months post-infection, though they may persist for years. 59 The natural kinetics of anti-CHIKV antibodies in transplant patients are unknown.
Commercially available serological tests often lack sensitivity and specificity, and improvement of these assays is essential for proper diagnosis.
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| Advances in prevention and treatment
There 
| Clinical manifestations-adult and pediatric
Up to 80% of ZIKV infections are asymptomatic, while the remaining cases usually have mild, nonspecific symptoms such as fever, pruritic maculopapular rash, arthralgia, myalgia, conjunctivitis, and headache. Symptoms in children are thought to be similar to those seen in adults (Table 1) . 74, 75 ZIKV infection can be particularly devastating for pregnant women, as it has been linked to fetal loss and congenital Zika syndrome, leading the World Health Organization to declare the ZIKV epidemic as a global public health emergency. 76 Congenital Zika syndrome has been recently defined to include severe microcephaly, thin cerebral cortices with subcortical calcifications, macular scarring and focal pigmentary retinal mottling, congenital contractures, and marked early hypertonia and symptoms of extrapyramidal involvement; however, the full neurological sequelae of fetuses affected by ZIKV are yet to be described longitudinally. 77, 78 Infection with ZIKV can also cause neurological complications such as Guillain-Barre syndrome and potentially trigger ADEM. 74 Little is known about ZIKV infections in immunocompromised patients.
In addition to transmission through mosquito vectors and vertical transmission, ZIKV has been shown to be persistent in semen for at least 188 days after infection and can be transmitted sexually from men or women to their partners. [79] [80] [81] Persistence in semen exists despite negative blood-based screening assays. 82 Persistence in other organ systems is presently unknown. Breast milk, urine, and saliva have high viral nucleic acids when tested, 73, 83, 84 and one potential breast milk-associated transmission has occurred. 
| Infections in transplant patients
Infection causes viremia, even in the 80% of infected individuals who are asymptomatic, creating a scenario for high likelihood of transmission via organ or blood donation if donor symptom screening alone is used without specific testing for ZIKV. 86 Several SOT recipients are thought to have contracted ZIKV via their transplanted organ. 87 One heart transplant patient in Brazil contracted ZIKV meningoencephalitis 8 months after transplantation. Tacrolimus and mycophenolate mofetil were stopped to allow immune reconstitution, but he ultimately died of arrhythmia caused by organ rejection. 88 identical viral RNA, though both recipients remained asymptomatic. 86 ZIKV transmission was reported in Brazil from an asymptomatic blood donor, who later called the blood bank with symptoms, to a newly transplanted liver recipient who received those platelets during transplantation; the recipient did not develop symptoms. 89 In addition, ZIKV has been detected in the vitreous of an asymptomatic cornea donor, though the transmission risk through corneal transplant is unknown. 90 No cases of ZIKV infection of pediatric transplant recipients have been reported.
| Screening and diagnosis
Symptomatic individuals have ZIKV in blood for only 3-5 days after symptom onset, when RT-PCR testing could be positive. IgM testing is often used, but is challenging due to cross-reactivity with other
Flaviviruses, DENV in particular. 91 Virus can also be detected in saliva, urine, semen, and amniotic fluid, with the latter three often remaining positive for virus after serum tests become negative. 
| Advances in prevention and treatment
No licenced vaccine currently exists for ZIKV. There are currently >10 vaccine candidates in clinical trials. 94 As mentioned above, a combination CHIKV and ZIKV vaccine has been protective in mouse models. 69 Another vaccine based on the strategy for Ebola vaccination with a VSV vector, VSV-ZIKV, was highly protective against ZIKV infection in mice as soon as 3 days after vaccination. 95 As for specific therapies, a study in rhesus monkeys suggested that a DENV-specific antibody against the E-dimer epitope crossneutralized ZIKV and was effective as a prophylactic and a therapeutic agent. 96 Chloroquine administered to ZIKA-infected pregnant mice significantly attenuated vertical transmission and reduced the ZIKV load in the fetal brain. 97 Research on small molecule inhibitors is ongoing, but no candidates are in clinical trials. An additional challenge is the need for safety and effectiveness of medications for pregnant mothers, a group often excluded from clinical trials.
| Challenges in arbovirus screening and diagnosis
Given that many manifestations of these diseases are thought to be primarily driven by immune responses to infection, the symptoms of these emerging viral infections in immunocompromised patients may be nonspecific and unrecognizable, leading to missed or delayed diagnosis. The common symptoms of malaise and fever seen with these infections could suggest anything from expected postoperative course to rejection to a separate and serious infection, demonstrating the need for appropriate and standardized diagnostic testing when clinical suspicion arises, even if outside the expected window and especially in endemic areas. 98 As demonstrated with HIV, hepatitis B, and HCV, increased screening can lead to decreased risk of donor-derived infections from asymptomatic infected individuals donating organs and blood products. 86 However, blood-based screening and diagnosis present several challenges, including the lack of standardized testing and cross-reactivity among serologic tests for these viruses. 99 As with the case of traditional blood-borne pathogens (eg, HIV, HCV), assessment of donor epidemiological information, including residence in endemic areas, the presence of signs or symptoms of infection, and travel history, may help prevent donor-derived infections. However, the use of these questionnaires can be problematic in blood or organ donor screening, as symptoms are often nonspecific or absent and as questionnaires are not instructive in endemic areas. Moreover, it can be costly and time-consuming to change questionnaire-based screening practices, let alone adding additional laboratory testing.
100
In addition to screening for these pathogens, other methods of protecting blood products have been investigated, such as a combined treatment with Amotosalen, a nucleic acid crosslinker, and UV light, a system that inactivates the RNA genome of many pathogens.
This method was demonstrated to be effective against ZIKV. practice safe sex to decrease transmission risk until donation. 103 If a potential donor contracts ZIKV, it is recommended that they defer donation for 120 days. Thirty-day donor deferral is recommended for CHIKV, and no deferral is yet recommended for DENV; however, living donors are encouraged to report any symptom development in the first week after donation. 104 Although there is great variability in the screening policies and reporting of transmission events of donorderived arbovirus infections from procurement agencies within and among nations, advances in donor screening, standards of investigation, and improvements in reporting and data sharing will allow for enhanced transplant safety. 105 
| CON CLUS IONS
The quickly changing epidemiology of the viruses highlighted in this review is multifactorial and related to international travel, increased vector range due to climate change, trade, inadequate vector control, viral adaptation, and increasing human populations. Broader circulation of these arboviruses leads to increased exposure risk to naïve populations, which can cause large outbreaks in new regions.
Infection with DENV, CHIKV, or ZIKV is a global health concern and is of particular concern in the transplant community, especially with pediatric patients, since less is understood about infection in children and the immunocompromised. Most importantly, symptoms of these infections are nonspecific and can be confused with other post-transplant diagnoses such as acute rejection. In endemic regions in particular, infections with DENV, CHIKV, and ZIKV should be on the differential diagnosis for evaluation of the transplant patient. Although this review focuses on only three arboviruses, a large number of other mosquito-and tick-borne pathogens are currently circulating throughout the world and may also pose risks to transplant recipients. As more attention is drawn to these important pathogens in the transplant community, additional research and strategies to mitigate risk will alleviate the potential effects of these emerging arboviruses on transplant recipients.
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